Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

401. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. (Abstract)

Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. People with nonrheumatic atrial fibrillation who have had a transient ischemic attack or a minor ischemic stroke are at risk of recurrent stroke.The objective of this review was to assess the effect of anticoagulants for secondary prevention, after a stroke or transient ischaemic attack, in patients with nonrheumatic atrial fibrillation.The reviewer (...) searched the Cochrane Stroke Group trials register and contacted trialists.Randomised trials comparing oral anticoagulants (target International Normalised Ratio range 2.5 to 4.0) with control or placebo in people with nonrheumatic atrial fibrillation and a previous transient ischaemic attack or minor ischaemic stroke.One reviewer assessed trial quality and extracted data.Two trials involving 485 people were included. Anticoagulants reduced the risk of recurrent stroke by two-thirds (odds ratio 0.36

2000 Cochrane

402. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. (Abstract)

Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. People with nonrheumatic atrial fibrillation who have had a transient ischemic attack or minor ischemic stroke are at risk of recurrent stroke.The objective of this review was to compare the effect of anticoagulants with antiplatelet therapy, for secondary prevention, in people with nonrheumatic atrial fibrillation and previous (...) cerebral ischaemia.The reviewer searched the Cochrane Stroke Group trials register and contacted trialists.Randomised trials comparing oral anticoagulants with aspirin in patients with non-rheumatic atrial fibrillation and a previous transient ischaemic attack or minor ischaemic stroke.One reviewer extracted the data.One trial was included, involving 455 patients. They received either anticoagulants (International Normalised Ratio 2.5 to 4.0), or 300 milligrams of aspirin per day. People joined

2000 Cochrane

403. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. (Abstract)

Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Non-valvular atrial fibrillation (AF) is associated with an increased risk of stroke.The objective of this review was to characterize the efficacy and safety of oral anticoagulation (OAC) with vitamin K antagonists for the primary prevention of stroke in patients with chronic AF.We searched the Cochrane Stroke Group Specialised Register

2000 Cochrane

404. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. (Abstract)

Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Oral anticoagulants and aspirin are antithrombotic drugs that are commonly used in patients with vascular disease. We investigated whether either of these treatments prevented more effectively than the other bypass complications after infrainguinal bypass surgery.We did a multicentre, randomised, open trial. 2690 patients who had (...) undergone infrainguinal grafting were randomly assigned oral anticoagulants (target international normalised ratio 3.0-4.5, n=1339) or aspirin (80 mg daily, n=1351). We followed up patients for a mean of 21 months. The primary outcome was graft occlusion.308 graft occlusions occurred in the oral-anticoagulants group compared with 322 in the aspirin group (hazard ratio 0.95 [95% CI 0.82-1.11]), which suggested no overall advantage for either treatment. Oral anticoagulants were beneficial in patients

2000 Lancet Controlled trial quality: predicted high

405. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. (Abstract)

Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. The length of time after an episode of venous thromboembolism during which the risk of newly diagnosed cancer is increased is not known, and whether vitamin K antagonists have an antineoplastic effect is controversial.In a prospective, randomized study of the duration of oral anticoagulation (six weeks or six months) after a first episode of venous thromboembolism (...) for newly diagnosed cancer was 3.4 (95 percent confidence interval, 2.2 to 4.6) during the first year after the thromboembolic event and remained between 1.3 and 2.2 for the following five years. Cancer was diagnosed in 66 of 419 patients (15.8 percent) who were treated for six weeks with oral anticoagulants, as compared with 45 of 435 patients (10.3 percent) who were treated for six months (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.4). The difference was mainly due to the occurrence

2000 NEJM Controlled trial quality: uncertain

406. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. (Abstract)

Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Vitamin K antagonist treatment is effective for prevention and treatment of thromboembolic events but frequent laboratory control and dose-adjustment are essential. Small portable devices have enabled patient self-monitoring of anticoagulation and self-adjustment of the dose. We compared this self-management of oral anticoagulant therapy with conventional management (...) by a specialist anticoagulation clinic in a randomised cross-over study.50 patients on long-term oral anticoagulant treatment were included in a randomised controlled crossover study. Patients were self-managed or were managed by the anticoagulation clinic for a period of 3 months. After this period the alternative strategy was followed for each patient. Prothrombin time (expressed as international normalised ratio [INR]) were measured at intervals of 1-2 weeks in both periods without knowledge of type

2000 Lancet Controlled trial quality: uncertain

407. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials

Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials Pinede (...) L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel J P Authors' objectives To assess the length of oral anticoagulation therapy (short versus long duration) after a first episode of venous thromboembolism (VTE). Searching MEDLINE and EMBASE were searched without language restrictions using the following keywords and textwords: 'randomised controlled trials', 'clinical trials', 'prospective studies', 'thrombophlebitis', 'deep vein thrombosis', 'pulmonary embolism', 'thromboembolism', 'venous

2000 DARE.

408. Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty

Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty Wade W E, Hawkins D W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) studies are needed before a definitive recommendation can be made. Clinicians may choose combination prophylaxis until the results of more definitive studies become available. Source of funding Dr Wade received an honoraria from Rhone-Poulenc Rover for writing this article, and Dr Hawkins is a consultant with Rhone-Poulenc Rover. Bibliographic details Wade W E, Hawkins D W. Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty. Orthopedics 2000; 23(4): 335-338

2000 NHS Economic Evaluation Database.

409. Evaluation of an alternative model of anticoagulant care

Evaluation of an alternative model of anticoagulant care Evaluation of an alternative model of anticoagulant care Evaluation of an alternative model of anticoagulant care Hennessy B J, Vyas M, Duncan B, Allard S A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Introduction of a nurse specialist supervised, computer assisted warfarin-dosing system (CDSS) in the delivery of anticoagulant care. The nurse-led service operates as follows: on starting warfarin patients are counselled for approximately 25 minutes by the nurse specialist before being reviewed by the doctor. The nurse specialist then follows them up in the return clinic until their international normalised ratio (INR) is stable. Patients who are experiencing problems

2000 NHS Economic Evaluation Database.

410. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost-effectiveness analysis

Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost-effectiveness analysis Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost-effectiveness analysis Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost-effectiveness analysis Lafata J E, Martin S A, Kaatz S, Ward R E Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The management of patients on chronic warfarin therapy by either: anticoagulation clinic testing (in-clinic capillary monitors with immediate test results); patient self-testing (at-home capillary monitors with immediate test results telephoned by patients to an organised

2000 NHS Economic Evaluation Database.

411. Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia

Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia Kalafut M A, Gandhi R, Kidwell C S, Saver J L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a subcutaneous injection of low molecular weight heparin (LMWH) as a bridging anticoagulant therapy for patients with acute and subacute cerebral ischaemia. Patients received enoxaparin (1 mg/kg twice daily), and warfarin was initiated on the same day as the start of LMWH therapy

2000 NHS Economic Evaluation Database.

412. Anticoagulation management in primary care: a trial-based economic evaluation

Anticoagulation management in primary care: a trial-based economic evaluation Anticoagulation management in primary care: a trial-based economic evaluation Anticoagulation management in primary care: a trial-based economic evaluation Parry D, Fitzmaurice D, Raftery J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) on anticoagulation therapy. There was an increased cost of treating patients in primary care, and at no point did primary care become a lower cost option than secondary care. Local decision-makers need to assess the increased cost of anticoagulation management in primary care, in terms of the potential reductions in high-cost serious adverse events. CRD COMMENTARY - Selection of comparators The choice of the comparator was justified because the hospital administration of anticoagulation is the traditional method

2000 NHS Economic Evaluation Database.

413. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. (Abstract)

A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. Control of oral anticoagulation therapy has been reported to often be inadequate. Previous retrospective investigations suggest that patients' self-adjustment of oral anticoagulants may lead to improved control.To investigate the effects of patients' self-management of oral anticoagulation (...) therapy on accuracy of control and measures of treatment-related quality of life.Randomized, single-blind, multicenter trial.A total of 179 patients receiving long-term oral anticoagulation treatment were enrolled at 5 referral centers in Germany.Patients were randomized to an oral anticoagulation self-management group based on a structured treatment and teaching program and international normalized ratio (INR) self-monitoring. The control group received conventional care as provided by family

1999 JAMA Controlled trial quality: predicted high

414. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. (Abstract)

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. Patients who have a first episode of venous thromboembolism in the absence of known risk factors for thrombosis (idiopathic thrombosis) are often treated with anticoagulant therapy for three months. Such patients may benefit from longer treatment, however, because they appear to have an increased risk of recurrence after anticoagulant therapy is stopped.In (...) this double-blind study, we randomly assigned patients who had completed 3 months of anticoagulant therapy for a first episode of idiopathic venous thromboembolism to continue receiving warfarin, with the dose adjusted to achieve an international normalized ratio of 2.0 to 3.0, or to receive placebo for a further 24 months. Our goal was to determine the effects of extended anticoagulant therapy on rates of recurrent symptomatic venous thromboembolism and bleeding.A prespecified interim analysis

1999 NEJM Controlled trial quality: predicted high

415. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery

Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events (...) after infrainguinal bypass surgery Tangelder M J, Lawson J A, Algra A, Eikelboom B C Authors' objectives To determine the efficacy of antiplatelet therapy and oral anticoagulants in maintaining graft patency and preventing ischemic complications in patients after infrainguinal bypass surgery. Searching MEDLINE was searched from 1966 onwards using the keywords 'aspirin', 'acetylsalicylic acid', 'antiplatelet', '(oral) anticoagulants', 'anticoagulation', 'phenprocoumon', 'warfarin', 'peripheral

1999 DARE.

416. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis

Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis Anand S S, Yusuf S Authors' objectives To determine the effects of long-term oral anticoagulant (OA) therapy, stratified by intensity of anticoagulation and aspirin therapy, on outcomes in patients with CAD. Searching MEDLINE, EMBASE (...) . Specific interventions included in the review OAs for example, warfarin sodium, dicoumarol, marcoumar, phenprocoumon, acencoumarin, bishydroxycourmarin. Individual agents were not studied separately but results were stratified by intensity of anticoagulation. Participants included in the review Patients with coronary artery disease (CAD). Mean age ranged from 59.9 to 64.3 years. Outcomes assessed in the review The primary outcomes were: number of deaths, recurrent myocardial infarctions (MI), stroke

1999 DARE.

417. Clinical and economic effectiveness of an inpatient anticoagulation service

Clinical and economic effectiveness of an inpatient anticoagulation service Clinical and economic effectiveness of an inpatient anticoagulation service Clinical and economic effectiveness of an inpatient anticoagulation service Mamdani M M, Racine E, McCreadie S, Zimmerman C, O'Sullivan T L, Jensen G, Ragatzki P, Stevenson J G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Implementing a pharmacist-managed anticoagulation service for inpatient treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE). A 24-hour, 7-day/week pharmacist-managed anticoagulation service was established to provide dosing and monitoring of unfractionated heparin (UFH) and warfarin therapies at the request of a physician

1999 NHS Economic Evaluation Database.

418. Changes in bone density after exposure to oral anticoagulants: a meta-analysis

Changes in bone density after exposure to oral anticoagulants: a meta-analysis Changes in bone density after exposure to oral anticoagulants: a meta-analysis Changes in bone density after exposure to oral anticoagulants: a meta-analysis Caraballo P J, Gabriel S E, Castro M R, Atkinson E J, Melton L J Authors' objectives To determine the association between exposure to oral anticoagulants and changes in bone density. Searching MEDLINE and EMBASE were searched until April 1998 using the following (...) keywords: 'bone', 'bone density', 'densitometry' and 'osteoporosis' combined with 'vitamin K' , 'anticoagulants' plus 'oral administration', 'coumarins', '4-hydroxycoumarins' and specific names of oral anticoagulants. Reference lists of pertinent publications were handsearched. Experts on the topic were also consulted. No language restrictions were applied. Study selection Study designs of evaluations included in the review Publications reporting original data on the effect of oral anticoagulants

1999 DARE.

419. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research (Abstract)

Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research We aimed to evaluate low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease (IHD).5499 men aged between 45 years and 69 years at high risk of IHD were recruited from 108

1998 Lancet Controlled trial quality: predicted high

420. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. (Abstract)

Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. The demand for anticoagulant treatment is increasing. We compared the benefits of computer-generated anticoagulant dosing with traditional dosing decided by experienced medical staff in achieving target international normalised ratios (INRs).In five European centres we randomly assigned 285 patients in the stabilisation period and stabilised patients to the computer-generated-dose (...) group (n=137) or traditional-dose group (n=148). Centres had a specialist interest in oral anticoagulation but no previous experience with computer-generated dosing. The computer program calculated doses and times to next visit. Our main endpoint was time spent in target INR range (Rosendaal method).For all patients combined, computer-generated dosing was significantly beneficial overall in achieving target INR (p=0.004). The mean time within target INR range for all patients and all ranges was 63.3

1998 Lancet Controlled trial quality: uncertain